Change in eGFR after adminstration of tolvaptan and furosemide in liver cirrhosis patients with ascites:a randomized study

Change in eGFR after adminstration of tolvaptan and furosemide in liver cirrhosis patients with ascites:a randomized study - Change in eGFR after adminstration of tolvaptan and furosemide in liver cirrhosis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023881

Enrollment

Registered

2016-09-03

Start date

2016-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Change from the conventional diuretics to the tolvaptan continuous administration of the conventional diuretics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with liver cirrohsis with ascites in hepatic edema. Diagnosis of liver cirrhosis was based on laboratory results and imaging tests 2)Patients given oral furosemide 40-100mg/day and Spironolactone 25mg-200mg at the time of enrolling.

Exclusion criteria

Exclusion criteria: 1)The anuric patients 2)Patients with urinary retention 3)Serum Na >=147mEq/L

Design outcomes

Primary

Measure	Time frame
Change in eGFR levels from baseline after adminstraion of diuretic for 24 weeks	—

Countries

Japan

Contacts

Public ContactHyun Sung Ji

shonan kamakura general hospital department of gastroenterology

sjh343434@yahoo.co.jp0467-46-1717

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026